- Academic Affairs
- Administration and Finance
- Center for Health and Homeland Security
- Center for Information Technology Services
- Communications and Public Affairs
- Office of Philanthropy
- Government Affairs
- Human Resource Services
- Office of Community Engagement
- Operations and Planning
- Office of the President
- Police and Public Safety
- Research and Development
- University Counsel
Rodney J. Taylor, MD, MSPH, FACS
Rodney J. Taylor MD, MSPH, is an associate professor in the Department of Otorhinolaryngology-Head & Neck Surgery at the University of Maryland of School of Medicine.
Taylor is the director of general otorhinolaryngology at the School of Medicine and the chief of otolaryngology at the Baltimore VA Medical Center. He joined the faculty of the Department of Otorhinolaryngology in 2001. Taylor has been recognized by local and national organizations as one of "America’s Top Otolaryngologists."
Taylor graduated cum laude in 1991 from Harvard College, where he was senior class president and a varsity football player and received the Francis Burr Award for character, leadership, and athletic ability. He graduated from Harvard Medical School in 1995, receiving his MD while also serving as an academic advisor and counselor for Harvard College premed students.
After medical school, Taylor spent six years at the University of Michigan completing his residency in Otolaryngology-Head & Neck Surgery. At Michigan, he spent a year developing novel techniques in head and neck cancer surgery and developed and studied quality of life instruments among head and neck cancer patients. Taylor also received his Master of Science in Public Health from the University of Michigan School of Public Health in 1999.
Taylor is the associate chair of research in the Department of Otolaryngology-Head & Neck Surgery. He oversees more than 20 full-time personnel in a laboratory with multiple grants, including six NIH/federal grants. Taylor’s lab has focused on factors impacting immunocytotoxicity and immune-tolerance using cancer cell lines and mouse tumor models.
Based upon findings from his laboratory, he initiated and completed a multi-institutional clinical trial evaluating the impact of Natural Killer cells receptor polymorphisms on antibody-based therapy for HNC. This work has provided insight into which patient best benefit from antibody-based therapy for SCCHN. His lab currently collaborates with Dr. Zalzman’s lab and he has successfully established mouse models to study head and neck cancer cell immortality mechanisms and behavior using xenografts.
Taylor's specialties include head and neck surgical oncology, rhinology and sinus disease, endocrine surgery (thyroid and parathyroid), sleep apnea, and robotic surgery.